LONDON (Alliance News) - Technology commercialisation and investment company Imperial Innovations Group PLC on Wednesday said portfolio company Kesios Therapeutics has closed a GBP19.0 million Series A funding round.
Imperial said it has invested GBP6.0 million in the funding round and will now hold a 42% stake in the company.
Kesios is developing treatments for multiple myeloma and other cancers.
"The company's lead drug candidate is about to enter clinical studies and with this substantial Series A financing behind it, this team is in a strong position to deliver a new treatment option for patients with multiple myeloma," said Maina Bhaman, director of healthcare ventures at Imperial.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.